Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319981 · ClinicalTrials.gov registry record · Phase 2
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01319981: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01319981 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01319981, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if intensive chemotherapy (hyper-CVAD therapy) given in combination with liposomal vincristine (Marqibo), in addition to rituximab for patients who are CD20 positive and/or imatinib, dasatinib, or ruxolitinib for patients with the Philadelphia (Ph) chromosome, can help to control ALL or lymphoblastic lymphoma. The safety of this treatment will also be studied. CD20 is a protein "marker" that is found in leukemia or lymphoma cells. This is an investigational study. Liposomal vincristine is FDA approved for the treatment of patients with CLL who have relapsed at least 2 times. All of the other study drugs used in this study are FDA approved and commercially available. The combination of liposomal vincristine with the other study drugs is also being used in research only. Up to 65 patients will take part in this study. All will be enrolled at MD Anderson.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Mesna
- DRUG Rituximab
- DRUG Imatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-03-05 |
| Est. Completion | 2020-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01319981
The ClinicalTrials.gov registry entry for NCT01319981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01319981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01319981 about?
NCT01319981 is a clinical study titled "Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia". Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if intensive chemotherapy (hyper-CVAD therapy) given in combination with liposomal vincristine (Marqibo), in addition to rituximab for patie...
What is the current status of trial NCT01319981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2013-03-05. Estimated completion is 2020-11-11.
What interventions are being tested in trial NCT01319981?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Mesna (DRUG), Rituximab (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT01319981?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.